// App-Quantinova.ai

S298 : CS585 IS A FIRST-IN-CLASS COMPOUND TARGETING THE IP RECEPTOR FOR PREVENTION OF THROMBOSIS WITHOUT INCREASED RISK OF BLEEDING

Researchers

Presenter

  • Sylviane Lambert

Principal Investigators

  • Reheman Adili

  • Bjorn Dahlof

  • Andrew White

  • Michael Holinstat

Medical Centers

  • Pharmacology,University of Michigan Medical School,Ann Arbor,Vereinigte Staaten

  • Cereno Scientific,Gothenburg,Suecia

  • Medicinal Chemistry,University of Michigan Medical School,Ann Arbor,Esta

  • Cereno Scientific, Gothenburg, Sweden

  • Pharmacology,University of Michigan Medical School,Ann Arbor,Vereinigte Staaten

  • Cereno Scientific, Gothenburg, Sweden

  • Cereno Scientific, Gothenburg, Sweden

  • Medicinal Chemistry,University of Michigan Medical School,Ann Arbor,Esta

  • Pharmacology,University

  • Cereno Scientific,Gothenburg,Suecia

  • Medicinal Chemistry,University of Michigan Medical School,Ann Arbor,Esta

  • Cereno Scientific,Gothenburg,Швеция

  • Medicinal Chemistry,University of Michigan Medical School,Ann Arbor,Esta

  • Pharmacology,University of Michigan Medical School,Ann Arbor,Estados Unidos

  • Medicinal Chemistry,University of Michigan Medical School,Ann Arbor,Esta

  • Cereno Scientific,Gothenburg,Suecia

  • Institute o

  • Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden

  • Pharmacology,University of Michigan Medical School,Ann Arbor,Vereinigte Staaten

  • Pharmacology,University of Michigan Medical School,Ann Arbor,Vereinigte Staaten

  • Cereno Scientific, Gothenburg, Sweden

  • Cereno Scientific, Gothenburg, Sweden

Locations

  • United States

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Prostacyclin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved